Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study

Acta Oncologica

Volumn 54, Issue 10, 2015, Pages 1754-1762

  Trip, Anouk K ^a   Stiekema, Jurriën ^a   Visser, Otto ^b   Dikken, Johan L ^a,c   Cats, Annemieke ^a   Boot, Henk ^a   Van Sandick, Johanna W ^a   Jansen, Edwin P M ^a   Verheij, Marcel ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Department of Cancer Registry and Research   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; ESOPHAGOGASTRIC JUNCTION CANCER; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SOCIAL STATUS; STOMACH CANCER; ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL JUNCTION; MIDDLE AGED; NETHERLANDS; PATHOLOGY; STOMACH NEOPLASMS; TRENDS; UNIVERSITY HOSPITAL; UTILIZATION;

ACADEMIC MEDICAL CENTERS; ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; STOMACH NEOPLASMS;

EID: 84946209212     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2015.1009638     Document Type: Article

References (23)

1. Netherlands Cancer Registry. Available from: http://www.cijfersoverkanker.nl. [cited 2014 Dec 19].
2. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-49.
3. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347: 1662-9.
4. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE-5-a population-based study. Lancet Oncol 2014; 15: 23-34.
5. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-84.
6. Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
7. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012; 30: 2327-33.
8. Cronin-Fenton DP, Mooney MM, Clegg LX, Harlan LC. Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma. World J Gastroenterol 2008; 14: 3165-73.
9. Schonnemann KR, Mortensen MB, Bjerregaard JK, Fristrup C, Pfeiffer P. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer. Acta Oncol 2014; 53: 385-91.
10. Schouten LJ, Jager JJ, van den Brandt PA. Quality of cancer registry data: A comparison of data provided by clinicians with those of registration personnel. Br J Cancer 1993; 68: 974-7.
11. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. AJCC cancer staging manual, 7th ed. New York: Springer; 2010.
12. Sherman KL, Merkow RP, Bilimoria KY, Wang CE, Mulcahy MF, Benson AB, et al. Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States. Ann Surg Oncol 2013; 20: 362-70.
13. Coburn NG, Guller U, Baxter NN, Kiss A, Ringash J, Swallow CJ, et al. Adjuvant therapy for resected gastric cancer-rapid, yet incomplete adoption following results of intergroup 0116 trial. Int J Radiat Oncol Biol Phys 2008; 70: 1073-80.
14. Coburn NG, Lourenco LG, Rossi SE, Gunraj N, Mahar AL, Helyer LK, et al. Management of gastric cancer in Ontario. J Surg Oncol 2010; 102: 54-63.
15. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305-13.
16. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-7.
17. Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J. Survival after neoadjuvant therapy compared with surgery alone for resectable esophageal cancer in a population-based study. World J Surg 2006; 30: 2182-90; discussion 91-2.
18. Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, Jansen EP, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 2011; 11: 329.
19. Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010; 28: 2430-6.
20. Stiekema J, Trip AK, Jansen EP, Boot H, Cats A, Ponz OB, et al. The prognostic significance of an r1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Ann Surg Oncol 2014; 21: 1107-14.
21. Dikken JL, Dassen AE, Lemmens VE, Putter H, Krijnen P, van der Geest L, et al. Effect of hospital volume on postoperative mortality and survival after oesophageal and gastric cancer surgery in the Netherlands between 1989 and 2009. Eur J Cancer 2012; 48: 1004-13.
22. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-37.
23. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349: 2117-27.